AbbVie

ABBV Mega Cap

Healthcare · Drug Manufacturers - General

Updated: Apr 5, 2026, 00:03 UTC

$208.84

-2.86% today

52W: $164.39 – $244.81

52W Low: $164.39 Position: 55.3% 52W High: $244.81

🔗 Compare Brokers Best Broker for Beginners →

Key Metrics

P/E Ratio

88.49x

Price-to-Earnings

Forward P/E

12.96x

Forward Price/Earnings

P/S Ratio

6.04x

Price-to-Sales

EV/EBITDA

14.78x

Enterprise Value/EBITDA

Div. Yield

331%

Annual dividend yield

Market Cap

$369.4B

Market Capitalization

Revenue Growth

10%

YoY Revenue Growth

Profit Margin

6.91%

Net profit margin

ROE

6225%

Return on Equity

Beta

0.36

Market sensitivity

Short Interest

1.58%

% of float sold short

Avg. Volume

7,382,714

Average daily volume

Valuation Analysis

Signal

Overvalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

29 analysts

Avg. Price Target

$249.14

+19.3% upside

Target Range

$184.00 – $299.00

🚫 Not currently held by any of our 15 tracked Smart Money managers. View Smart Money Tracker →

About the Company

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face;

Sector: Healthcare Industry: Drug Manufacturers - General Country: United States Employees: 57,000 Exchange: NYQ